Nissha Co.ltd. · TSE:7915
Nissha Co.ltd — FY2025 Earnings Presentation
28 slides from Nissha Co.ltd's earnings presentation, Feb 12, 2026
Slide 1: Financial Results for FY2025.12
Financial Results for FY2025.12 Ended December 31, 2025 February 12, 2026 (Corrected on March 23, 2026) Junya Suzuki Chairman of the Board and Group CEO Nissha Co., Ltd.
Slide 2: Contents
Contents FY2025 Results FY2026 Plan Reinforcing and Rationalizing the Business Portfolio ©2026 Nissha Group 2
Slide 3: FY2025 Results
FY2025 Results ©2026 Nissha Group 3
Slide 4: Highlights
Highlights FY2025 Results Tailwinds Industrial Materials: Steady demand continued for decorative products, mass production of new mobility products (exterior functional components) started in Q3 Devices: The impact of demand decrease mitigated by the factory consolidation, resulting in profit
Slide 5: FY2025 (Full-year) Results
FY2025 (Full-year) Results （Millions of JPY） 2024 2025 2025 VS. Previous Results Previous Forecast Results YoY forecast Net sales 195,598 191,300 194,898 -0.4% 3 +1.9% Industrial Materials 74,090 74,300 76,315 +3.0% +2.7% Devices 67,542 58,000 58,452 -13.5% +0.8% Medical Technologies 45,622 46,000 4
Slide 6: FY2025 Q4 (3 months) Results
FY2025 Q4 (3 months) Results （Millions of JPY） 2024 Q4 2025 Q3 2025 Q4 Results Results Results YoY QoQ Net sales 47,196 48,221 49,627 +5.1% +2.9% Industrial Materials 18,776 19,504 19,240 +2.5% -1.4% Devices 14,161 14,074 14,625 +3.3% +3.9% Medical Technologies 11,984 11,588 12,083 +0.8% +4.3% Other
Slide 7: Industrial Materials: FY2025 Q4 (3 months) Results
Industrial Materials: FY2025 Q4 (3 months) Results Quarterly net sales and operating profit margin ■Sustainable Materials (Metallized paper and others) ■Decoration (Home appliances and others) Net sales QoQ (Forex: JPY150/$) ■Decoration (Mobility) Decoration: Sales lifted by new ●Operating profit
Slide 8: Devices: FY2025 Q4 (3 months) Results
Devices: FY2024 Q4 (3 months) Results Quarterly net sales and operating profit margin ■ Handheld terminals (logistics related), Mobility, Gaming devices, Gas sensors and others Net sales QoQ (Forex: JPY150/$) ■ Tablet devices ■ Smartphones ● Operating profit margin Tablets: Steady demand （Million
Slide 9: Medical Technologies: FY2025 Q4 (3 months) Results
Medical Technologies: FY2025 Q4 (3 months) Results Quarterly net sales and operating profit margin ■Business media ■Medical devices (Own brand) 2025 Q3 Q4 Net sales QoQ (Forex: JPY150/$) ■Medical devices (CDMO) Medical devices (CDMO): Demand Forex (Average) ¥145/$ ¥150/$ ●Operating profit margin
Slide 10: Pharmaceuticals: FY2025 Q4 (3 months) Results
Pharmaceuticals: FY2025 Q4 (3 months) Results Quarterly net sales Net sales QoQ ■Pharmaceuticals, etc. New items launched, in addition to ■OTC Pharmaceutical CDMO (Shigaken Pharm.) steady demand （Millions of JPY） OTC Pharmaceutical CDMO: 2,000 1,890 Ordered 40.0% business expanded 1,676 1,751
Slide 11: FY2026 Plan
FY2026 Plan ©2026 Nissha Group 11
Slide 12: FY2026 Plan
FY2026 Plan Full-year: YoY decrease in net sales, increase in operating profit Half-year: Demand increase in H2, resulting in operating profit improving Quarter: Weak demand for tablets in Devices in Q1, resulting in operating loss in Q1 forecasted Full-year Half-year Quarter ■■ Net sales (Mil
Slide 13: FY2026 Net Sales Variance: YoY decrease, recovery in H2
210 FY2026 Net Sales Variance: 205 YoY decrease, recovery in H2 (Billions of JPY) 2025 2026 200 Forex (Average) ¥148/$ ¥145/$ 2.3 195 194.8 ・Increase in decoration for mobility 0.1 0.1 191.5 190 ・Increase of exterior -5.9 ・Forex impact: functional components -1.0 billion yen ・Expansion of projects ・
Slide 14: FY2026 Operating Profit Variance: YoY increase
10.0 FY2026 Operating Profit Variance: 9.0 YoY increase 8.0 (Billions of JPY) 7.0 0.7 0.2 6.6 6.0 1.0 Elimination of temporary 5.0 0.5 Effect of costs recorded 4.0 0.3 divesting some in 2025 Demand business 4.0 Business increase developments Decrease in portfolio Demand Elimination Demand fixed cost
Slide 15: FY2026 Plan
FY2026 Plan （Millions of JPY） FY2025 FY2026 FY2025 FY2025 FY2026 FY2026 Full-year Full-year H1 H2 H1 H2 YoY Results Plan Results Results Plan Plan Net Sales 194,898 97,049 97,849 191,500 87,500 104,000 -1.7% Industrial Materials 76,315 37,570 38,745 78,600 37,000 41,600 +3.0% Devices 58,452 29,752 2
Slide 16: Reinforcing and Rationalizing the Business Portfolio
Reinforcing and Rationalizing the Business Portfolio ©2026 Nissha Group 16
Slide 17: Reinforcing and Rationalizing the Business Portfolio: Disciplined diversification
Reinforcing and Rationalizing the Business Portfolio: Disciplined diversification 2010s 2020s（through the present） Toward 2030 Overreliance Building a business portfolio through Selective and on the IT devices selective focus and diversification disciplined diversification Highly volatile Selective
Slide 18: Enhancing ROE through improving operating profit margin
Enhancing ROE through improving operating profit margin ROE has remained low, falling below the cost of equity (6-8％*) ROE has been linked to the operating profit margin Improving operating profit margin through selective and disciplined diversification 20% ROE (left axis) Operating profit mar
Slide 19: Growth potential
Selective and disciplined diversification, prioritizing profitability over business expansion Active investment in high-profit business Star Problem Child high Medical devices CDMO Company-wide commitment to the （U.S.） Mobility exterior functional components medical market Pharmaceuticals CDMO Med
Slide 20: Company-wide Commitment to the Medical Market
Company-wide Commitment to the Medical Market Contributing to solving medical issues and enriching people’s healthy and affluent lives Medical devices market Pharmaceuticals market High turnover of existing assets Expansion through investment Design & Prescription Medical Development Technologies OT
Slide 21: Acquisition of USM Healthcare, Vietnamese medical devices manufacturer
Devices Acquisition of USM Healthcare, Vietnamese medical devices manufacturer Company USM Healthcare Medical Devices A new business platform in Southeast Asia Name Sole domestic stent manufacturer in Vietnam Location Ho Chi Minh City, Vietnam Expanding medical devices CDMO business in Establi
Slide 22: Cash allocation (progress in the second year of the 8th medium-term business plan)
Corrected on March 23, 2026 (Corrections are underlined.) Cash allocation (progress in the second year of the 8th medium-term business plan) 80,000 Cash-in 80,000 Cash-out FY2024-2026 FY2024/2025 FY2024-2026 FY2024/2025 70,000 3-year plan 2-year results 70,000 3-year plan 2-year results Progress 95%
Slide 23: Dividend
Dividend Plan to continue annual dividend of 50 yen per share, looking to medium- to long-term growth Annual dividends per share Ordinary dividend (Interim) Ordinary dividend (Year-end) Special dividend JPY50 JPY50 JPY50 JPY50 JPY50 JPY40 25 25 25 25 JPY30 10 35 15 15 25 25 25 25 15 15 15 2020 2021
Slide 24: Initiatives enabling portfolio management
Initiatives enabling portfolio management Utilizing diverse human capital 27.7% 28.6% 30.9% 28.0% 33.1% 27.0% Female manager ratio (Japan, Nissha non- 23.9% 24.5% consolidated): reached 10% 10.1% Next-generation female manager ratio: 5.9% 7.1% 8.9% steadily increasing Responding to climate chang
Slide 25: (Reference) Capital investment, Depreciation and amortization, R&D
(Reference) Capital investment, Depreciation and amortization, R&D Depreciation and Capital investment R&D amortization (Millions of JPY) (Millions of JPY) (Millions of JPY) 15,000 15,000 10,000 11,707 10,000 10,000 10,360 10,300 9,611 9,542 9,137 8,700 5,000 7,559 4,656 4,437 4,124 5,000 5,000 3,60
Slide 26: (Reference) Capital investment, Depreciation and amortization, M&A investment, R&D (FY2025)
(Reference) Capital investment, Depreciation and amortization, M&A investment, R&D (FY2025) (Millions of JPY) Q1 Results Q2 Results Q3 Results Q4 Results Capital investment 3,033 3,413 2,728 2,532 Depreciation and 2,506 2,464 2,689 2,700 amortization M&A investment 9,500 291 0 3,840 R&D 1,034 1,051
Slide 27: (Reference) External ESG evaluations
（Reference）External ESG evaluations ESG rating agencies MSCI ESG Ratings: “AA” Index Selected in 4 out of the 6 ESG indexes adopted by GPIF FTSE JPX Blossom Japan Index FTSE JPX Blossom Japan Sector Relative Index MSCI Japan ESG Select Leaders Index S&P/JPX Carbon Efficient Index Oth
Slide 28: Forward-looking information disclaimer
Among the information included in this presentation and provided at investor briefings and conferences, performance targets, plans, outlooks, strategies and other information that is not constituted of actual past facts, is information that has been judged reasonable by the managers of the Company b